Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093

Krayem, Mohammad; Sabbah, Malak; Najem, Ahmad; Wouters, An; Lardon, Filip; Simon, Stephane; Sales, François; Journe, Fabrice; Awada, Ahmad; Ghanem, Ghanem E.; Van Gestel, Dirk

doi:10.3390/cancers15245860

Open AccessCorrection

Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093

by

Mohammad Krayem

^1,2,*

,

Malak Sabbah

¹,

Ahmad Najem

¹

,

An Wouters

³

,

Filip Lardon

³

,

Stephane Simon

²,

François Sales

¹,

Fabrice Journe

^1,4,

Ahmad Awada

^1,5,

Ghanem E. Ghanem

¹ and

Dirk Van Gestel

²

¹

Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Rue Héger-Bordet 1, 1000 Brussels, Belgium

²

Department of Radiation Oncology, Institut Jules Bordet, Université libre de Bruxelles, 1000 Brussels, Belgium

³

Center for Oncological Research (CORE), University of Antwerp, 2610 Wilrijk, Belgium

⁴

Department of Human Anatomy and Experimental Oncology, Université de Mons (UMons), Research Institute for Health Sciences and Technology, 7000 Mons, Belgium

⁵

Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium

^*

Author to whom correspondence should be addressed.

Cancers 2023, 15(24), 5860; https://doi.org/10.3390/cancers15245860

Submission received: 25 October 2023 / Accepted: 14 November 2023 / Published: 15 December 2023

(This article belongs to the Collection Drug Resistance and Novel Therapies in Cancers)

Download Versions Notes

In the original article [1], there was a mistake in Figure 2A as published. The actin blot in our publication in Cancers (Figure 2A) had already been used in our published paper in Oncotarget in 2018. This is probably due to an error in our image saving. Note that this mistake does not change or alter the content and conclusions of our paper. The mistake indeed concerns control experiments, which were very easily reproduced. The corrected Figure 2A appears below.

In Figure 2B’s P53 panel, there are vertical splices between lanes 4/5 and 12/13. There are no apparent splices between these lanes in the other panels. This is because samples for every group (i.e., four conditions) were conducted on different membranes.

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

Krayem, M.; Sabbah, M.; Najem, A.; Wouters, A.; Lardon, F.; Simon, S.; Sales, F.; Journe, F.; Awada, A.; Ghanem, G.E.; et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093. [Google Scholar] [CrossRef] [PubMed]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Share and Cite

MDPI and ACS Style

Krayem, M.; Sabbah, M.; Najem, A.; Wouters, A.; Lardon, F.; Simon, S.; Sales, F.; Journe, F.; Awada, A.; Ghanem, G.E.; et al. Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093. Cancers 2023, 15, 5860. https://doi.org/10.3390/cancers15245860

AMA Style

Krayem M, Sabbah M, Najem A, Wouters A, Lardon F, Simon S, Sales F, Journe F, Awada A, Ghanem GE, et al. Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093. Cancers. 2023; 15(24):5860. https://doi.org/10.3390/cancers15245860

Chicago/Turabian Style

Krayem, Mohammad, Malak Sabbah, Ahmad Najem, An Wouters, Filip Lardon, Stephane Simon, François Sales, Fabrice Journe, Ahmad Awada, Ghanem E. Ghanem, and et al. 2023. "Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093" Cancers 15, no. 24: 5860. https://doi.org/10.3390/cancers15245860

APA Style

Krayem, M., Sabbah, M., Najem, A., Wouters, A., Lardon, F., Simon, S., Sales, F., Journe, F., Awada, A., Ghanem, G. E., & Van Gestel, D. (2023). Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093. Cancers, 15(24), 5860. https://doi.org/10.3390/cancers15245860

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093

Reference

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI